Corvus Pharmaceuticals Inc Stock
Corvus Pharmaceuticals Inc took a tumble today and lost -€1.060 (-8.170%).
We see a rather positive sentiment for Corvus Pharmaceuticals Inc with 9 Buy predictions and 1 Sell predictions.
With a target price of 27 € there is potential for a 126.61% increase which would mean more than doubling the current price of 11.92 € for Corvus Pharmaceuticals Inc.
Our community identified positive and negative aspects for Corvus Pharmaceuticals Inc stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corvus Pharmaceuticals Inc stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | -8.170% | -19.302% | -1.529% | 290.016% | 92.488% | 1115.816% | 422.588% |
| Sangamo Therapeutics Inc. | -10.030% | -53.171% | -61.677% | -85.041% | -70.869% | -92.335% | -98.960% |
| Evolus Inc | 2.510% | -6.031% | 23.198% | -57.192% | -22.239% | -41.945% | -42.340% |
| Rhythm Pharmaceuticals | -1.430% | -4.795% | 3.731% | 23.009% | -25.668% | 292.655% | 301.734% |
Comments
Corvus Pharmaceuticals (CRVS) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Show more
Ratings data for CRVS provided by MarketBeat
News
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
Corvus Pharmaceuticals (NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic
